Reagents and instruments for immunology, cell biology and molecular biology.

Emricasan [254750-02-2]

Print

Cat# NB-64-36061-1mL

Size : 1mLx10mM(inDMSO)

Brand : Neo Biotech

Request more information

Emricasan (Synonyms: PF 03491390, IDN-6556)

Catalog No. T6826 Copy Product Info

Purity: 99%

Emricasan (IDN-6556) is a pan-caspase inhibitor with irreversible properties. Emricasan has anti-inflammatory and anti-apoptotic activity and can be used in the treatment of infections and liver failure, etc. Emricasan also inhibits Zika virus infections.

Emricasan

Copy Product Info

Synonyms PF 03491390, IDN-6556

Cas No. 254750-02-2

Batch Information

Select Batch

Purity:99%

Color:White

Resource Download

COA

Product Introduction

Bioactivity

Description	Emricasan (IDN-6556) is a pan-caspase inhibitor with irreversible properties. Emricasan has anti-inflammatory and anti-apoptotic activity and can be used in the treatment of infections and liver failure, etc. Emricasan also inhibits Zika virus infections.
Targets&IC50	JFas cells:0.025 μM, THP-1 cells:0.27 μM, Caspase-8:0.4 nM, Caspase-3:0.31 nM
In vitro	METHODS: Primary rat cirrhotic hepatocytes were treated with Emricasan (50 µM) for 24 h, and mRNA expression levels were measured. RESULTS: Emricasan directly improved the expression of hepatocyte-specific markers. [1] METHODS: Human cervical cancer cells HeLa were pretreated with Emricasan (10 µM) for 1 h, then treated with vincristine (20 nM) for 44 h. Cell death was detected by Flow Cytometry. RESULTS: Emricasan eliminated 95% of vincristine-mediated cell death. [2]
In vivo	METHODS: To study the effects on chronic liver disease, Emricasan (10 mg/kg, 0.9% dimethylcarboxycellulose) was administered orally once daily for seven days to rats with advanced cirrhosis due to chronic CCl4 administration. RESULTS: Emricasan ameliorated hepatic sinusoidal microvascular dysfunction in cirrhotic patients, resulting in significant improvement in fibrosis, portal hypertension and liver function. [1] METHODS: To investigate the effects on cirrhosis, Emricasan (10 mg/kg) was administered intraperitoneally once daily for 10-20 days to C57BL/6 mice with secondary biliary cirrhosis induced by bile duct ligation (BDL). RESULTS: Emricasan treatment improved survival and portal hypertension (PHT) in a mouse model of long-term BDL. [3]
Cell Research	Astrocytes are mock-infected, treated with DMSO or treated with 2 μM niclosamide, 92 μM PHA-690509, 9 μM emricasan, or a combination of 92 μM PHA-690509 and 9 μM emricasan for 1 h before infection with PRVABC59 (MOI = 0.5). Cells are fixed 24 h after infection and stained for ZIKVE and nuclei.(Only for Reference)
Synonyms	PF 03491390, IDN-6556

Chemical Properties

Molecular Weight	569.5
Formula	C₂₆H₂₇F₄N₃O₇
Cas No.	254750-02-2
Smiles	C[C@H](NC(=O)C(=O)Nc1ccccc1C(C)(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)COc1c(F)c(F)cc(F)c1F
Relative Density.	1.386 g/cm3

Storage & Solubility Information

Storage

Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

H2O: < 1 mg/mL (insoluble or slightly soluble)

DMSO: 257.5 mg/mL (452.15 mM), Sonication is recommended.

Ethanol: 93 mg/mL (163.3 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (8.78 mM), Solution.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

Ethanol/DMSO

	1mg	5mg	10mg	50mg
1 mM	1.7559 mL	8.7796 mL	17.5593 mL	87.7963 mL
5 mM	0.3512 mL	1.7559 mL	3.5119 mL	17.5593 mL
10 mM	0.1756 mL	0.8780 mL	1.7559 mL	8.7796 mL
20 mM	0.0878 mL	0.4390 mL	0.8780 mL	4.3898 mL
50 mM	0.0351 mL	0.1756 mL	0.3512 mL	1.7559 mL
100 mM	0.0176 mL	0.0878 mL	0.1756 mL	0.8780 mL

Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.